Sentinel Lymph Node Working Group

Overview

About this study

The purpose of this study is to establish and analyze a large database on the outcomes of patients undergoing selective SLND, we hope to correlate a pattern of recurrence with selected patient characteristics. These results have the potential of giving physicians the ability to predict outcomes for future cancer patients and provide them a more effective course of treatment.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Patients diagnosed with Stage I or II melanoma 
  • Have undergone or will undergo selective SLND as standard treatment 
  • Patients who have undergone a SLND for a diagnosis other than melanoma
  • Any cutaneous skin cancers especially Merkel cell that undergo selective SLND

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Barbara Pockaj, M.D.

Contact us for the latest status

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20502643

Mayo Clinic Footer